AIM: The aim of the present study was to collect and compare cases of drug-induced PML in order to contribute to the debate about the role of the underlying diseases and/or drug immunosuppression in PML occurrence. METHODS: We searched for drug-induced PML cases in two international spontaneous adverse drug reaction (ADR) report databases, FDA-AERS and WHO-VigiBase. From MEDLINE, we retrieved case reports and case series containing the MESH term "leukoencephalopathy, progressive multifocal/chemically induced". In order to assess the PML-drug relationship, we analysed drug-reaction pairs in terms of the patients' underlying diseases and co-suspected drugs. RESULTS: Overall, 214 cases in FDA-AERS, 118 in WHO-VigiBase and 140 in MEDLINE were collected. Therapeutic groups more frequently involved in PML cases were monoclonal antibodies (MAbs), conventional immunosuppressive drugs and anti-HIV drugs. The most frequent underlying diseases were lymphoproliferative diseases (28%), autoimmune disorders (20%) and transplants (10%). MAbs were more often reported in cases where they were the only suspected drugs, whereas for the other therapeutic groups, concomitant drugs were reported. CONCLUSIONS: We found a strong relationship between PML and MAbs, especially when used in autoimmune diseases. PML is becoming a crucial issue of MAbs, since they can cause severe ADRs through the imbalance of the immune system. Based on these results, patients treated with MAbs should be carefully monitored for early signs and symptoms of PML.
AIM: The aim of the present study was to collect and compare cases of drug-induced PML in order to contribute to the debate about the role of the underlying diseases and/or drug immunosuppression in PML occurrence. METHODS: We searched for drug-induced PML cases in two international spontaneous adverse drug reaction (ADR) report databases, FDA-AERS and WHO-VigiBase. From MEDLINE, we retrieved case reports and case series containing the MESH term "leukoencephalopathy, progressive multifocal/chemically induced". In order to assess the PML-drug relationship, we analysed drug-reaction pairs in terms of the patients' underlying diseases and co-suspected drugs. RESULTS: Overall, 214 cases in FDA-AERS, 118 in WHO-VigiBase and 140 in MEDLINE were collected. Therapeutic groups more frequently involved in PML cases were monoclonal antibodies (MAbs), conventional immunosuppressive drugs and anti-HIV drugs. The most frequent underlying diseases were lymphoproliferative diseases (28%), autoimmune disorders (20%) and transplants (10%). MAbs were more often reported in cases where they were the only suspected drugs, whereas for the other therapeutic groups, concomitant drugs were reported. CONCLUSIONS: We found a strong relationship between PML and MAbs, especially when used in autoimmune diseases. PML is becoming a crucial issue of MAbs, since they can cause severe ADRs through the imbalance of the immune system. Based on these results, patients treated with MAbs should be carefully monitored for early signs and symptoms of PML.
Authors: Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Gian Luigi Mancardi; Maria Pia Amato; Roberto D'Alessandro; Filippo Drago; Clara Milanese; Patrizia Popoli; Leandro Provinciali; Pasqualino Rossi; Giovanni Savettieri; Gioacchino Tedeschi; Maria Rosaria Tola; Nicola Vanacore; Anna Covezzoli; Marisa De Rosa; Carlo Piccinni; Nicola Montanaro; Laura Periotto; Antonio Addis; Nello Martini Journal: Neurol Sci Date: 2008-09 Impact factor: 3.307
Authors: Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Colin O Wu; Neal S Young Journal: Blood Date: 2011-11-08 Impact factor: 22.113
Authors: Andrew M Posselt; Gregory L Szot; Lynda A Frassetto; Umesh Masharani; Mehdi Tavakol; Raj Amin; Joan McElroy; Marissa D Ramos; Robert K Kerlan; Lawrence Fong; Flavio Vincenti; Jeffrey A Bluestone; Peter G Stock Journal: Transplantation Date: 2010-12-27 Impact factor: 4.939
Authors: William H Kitchens; Divya Haridas; Maylene E Wagener; Mingqing Song; Mandy L Ford Journal: Transplantation Date: 2012-05-27 Impact factor: 4.939
Authors: Sean Warsch; Peter J Hosein; Michele I Morris; Uygar Teomete; Ronald Benveniste; Jennifer R Chapman; Izidore S Lossos Journal: Int J Hematol Date: 2012-06-09 Impact factor: 2.490
Authors: A M Posselt; M D Bellin; M Tavakol; G L Szot; L A Frassetto; U Masharani; R K Kerlan; L Fong; F G Vincenti; B J Hering; J A Bluestone; P G Stock Journal: Am J Transplant Date: 2010-08 Impact factor: 8.086